BACKGROUND Approximately one-half of patients undergoing diagnostic coronary angiography for angina have no significant coronary stenosis, in whom coronary functional abnormalities could be involved.
A pproximately one-half of patients undergoing diagnostic coronary angiography for typical chest pain have no significant coronary stenosis (1) . In such cases with suspected angina despite nonobstructive coronary arteries, coronary functional abnormalities could be involved, including increased vasoconstrictive reactivity and/or reduced vasodilator function (2) . Coronary microvessels are known to contribute to >50% of total coronary vascular resistance and regulate coronary blood flow (3) . Coronary microvascular dysfunction (CMD) is typically defined as increased resistance and/or impaired vasodilatation of those microvessels, leading to inadequate increase in blood flow in response to stress with resultant myocardial ischemia (3) (4) (5) .
Recent studies demonstrated that patients with CMD have significantly higher rates of cardiovascular events, indicating the importance of identification of such patients (4, 6, 7) . In the absence of flow-limiting stenosis, coronary circulation can be directly and separately assessed by coronary flow reserve (CFR) for the entire coronary tree and by index of microvascular resistance (IMR) for coronary microcirculation (7, 8) . Vasospastic angina (VSA) is also an important functional cardiac disorder caused by epicardial coronary spasm, which is caused by enhanced coronary vasoconstricting responses (2) . We have previously demonstrated that Rho-kinase plays a central role in the pathogenesis of coronary spasm (2, 9, 10) . test to assess coronary vasoconstricting responses and were also evaluated for their coronary microvascular vasodilatory function. We excluded patients with proven cardiomyopathy, significant valvular diseases (e.g., aortic stenosis), previous coronary stent implantation, relative contraindication for provocation test (e.g., bronchial asthma), renal failure, poor general condition, and unsuccessful procedures during physiological measurement and/or ACh provocation test. Finally, 187 consecutive patients who fulfilled the inclusion criteria were included in the present study ( Figure 1) .
ACH PROVOCATION TEST. The ACh provocation test was performed as previously described (9, 10) . Based on guidelines from the Japanese Circulation Society (11) , the positive provocation test for epicardial coronary spasm was defined as the development of >90% stenosis accompanied by chest pain and ischemic electrocardiographic changes.
In the present study, we defined microvas- CORONARY PHYSIOLOGICAL MEASUREMENTS. After ACh provocation testing, we administered ISDN intracoronarily to achieve dilatation of epicardial coronary arteries. We then performed coronary physiological measurements for FFR, CFR, and IMR in the left anterior descending coronary artery (LAD) during hyperemia induced by intravenous infusion of adenosine, as previously described (7, 8) . Furthermore, to evaluate the involvement of Rho-kinase, after the first measurement of CFR and IMR, we administered intracoronary fasudil (30 mg), a selective Rho-kinase inhibitor (2, 12) , and performed the second measurement of IMR. We calculated % changes in IMR before and after intracoronary fasudil as follows: (fasudil IMR À hyperemic IMR)/ hyperemic IMR.
CLINICAL OUTCOME AND PATIENT FOLLOW-UP. We defined major adverse cardiac events (MACE) as the composite of cardiac death, nonfatal myocardial infarction, and hospitalization due to unstable angina. We only counted the number of patients with the first occurrence of an event in the MACE during the follow-up period. Long-term follow-up was performed by using a questionnaire that was sent to patients and primary physicians, in addition to the information available on the medical records or telephone surveys. with the total observations, the observations with the events and those without the event were utilized. To calculate NRI, censored participants were handled as no events (15) . A p value <0.05 was considered to be statistically significant. Further information is available in the Online Methods.
RESULTS
CLINICAL PATIENT CHARACTERISTICS. The flow chart of the present study is shown in Figure 1 . We Table 1 ). The median IMR value was significantly higher in the VSA than non-VSA group, whereas CFR values were comparable between the 2 groups ( Figure 2 ). The distributions of patients according to IMR and CFR by each type of coexisting coronary reactivity abnormality are shown in Online Figure 1 .
Importantly, we found a highly negative correlation between IMR and CFR values in VSA patients, but not in non-VSA patients ( Figure 3 ).
CLINICAL OUTCOMES AND PROGNOSTIC PREDICTORS.
During the median follow-up period of 893 days (IQR: 637 to 1,136 days), there were 10 MACE in overall cohorts, including cardiovascular death (n ¼ 1) and hospitalization for unstable angina (n ¼ 9). Multivariable Cox proportional hazard analysis showed that high IMR significantly correlated with MACE in patients with chest pain and nonobstructive CAD ( Table 2) . Based on ROC curve analysis, the optimal IMR cutoff value for developing MACE was 18.0, and the area under the ROC curve was 0.76 (Online Figure 2 ). With this value, the sensitivity and specificity for predicting MACE were 90.0% and 63.4%, respectively, while negative predictive value was 99.1%. In multivariable logistic regression model for the presence of high IMR ($18.0), proven VSA was the strongest correlated predictor ( Table 3) Table 3 .
AMELIORATION OF IMR BY RHO-KINASE INHIBITION
WITH FASUDIL. To examine the involvement of Rhokinase activation in the pathogenesis of coronary functional abnormalities, we examined the effects of intracoronary fasudil, a selective Rho-kinase inhibitor (2, 12) . Importantly, fasudil significantly ameliorated IMR in G4 ( Figure 6A) , and % changes in IMR in response to intracoronary fasudil were more evident in G4 compared with the other 3 groups ( Figure 6B ).
Furthermore, there was a negative correlation between IMR and its %change after Rho-kinase inhibition in VSA but not in non-VSA patients (Online Figure 3 ).
DISCUSSION
The major findings of the present study are as fol- The satisfaction of the proportional hazards assumption of Cox regression models was confirmed by the testing using Schoenfeld residuals.
CI ¼ confidence interval; HR ¼ hazard ratio; VSA ¼ vasospastic angina; other abbreviations as in Table 1 . Tables 1 and 2 . (19) , although its prognostic impact and cut-off value to indicate CMD remain to be examined (7) . In the present study, we were able to elucidate, for the first time, the prognostic impact of IMR with the best cut-off value of 18.0 in patients with angina and nonobstructive CAD.
The cut-off value of IMR was considerably lower than that previously reported for CMD (IMR $25) (19, 20) , while increased IMR defined as >18.0 was significantly associated with proven VSA in the linear regression model ( (Figure 3) . In the present study, a close correlation was noted between coronary spasm and impaired coronary vasodilator responses in patients with chest pain and nonobstructive CAD, suggesting the presence of a common underlying mechanism for the abnormalities. Importantly, we were able to demonstrate that a selective Rho-kinase inhibitor, fasudil, significantly ameliorated impaired microvascular resistance in patients with increased IMR ($18.0) and proven VSA compared with other 3 groups. We have previously demonstrated that Rho-kinase activation plays a central role not only for epicardial coronary spasm (9, 10) , but also for coronary microvascular spasm (12) .
Furthermore, the present study demonstrates for the first time that Rho-kinase activation is simultaneously involved in epicardial coronary spasm and increased coronary microvascular resistance.
Furthermore, a negative correlation was noted between IMR and its %change after Rho-kinase inhibition only in VSA patients, indicating that increased IMR is associated with Rho-kinase activation in the 45  43  42  36  25  19  8  1  13  13  13  12  12  10  3  1  67  67  67  54  36  29  10  1  60  59  58  50  40  28  14  2 No. at Risk Negative during the follow-up. These issues also remain to be examined in future studies. 
